Formamide

Formamide

SCHEMBL27697391

CCCCC(=O)C1(N)CCCC1.NC=O

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.35
CES2 O00748 2/20 0.35
ALDH1A1 P00352 2/20 0.33
TP53 P04637 2/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
CA1 P00915 1/20 0.32
IAPP P10997 1/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
FAAH O00519 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
SOAT1 P35610 1/20 0.31
TRPA1 O75762 1/20 0.31
HSD17B3 P37058 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9130901 0.85 TDP1 (0.43) CES1CES2ALDH1A1MEN1KMT2A
SCHEMBL8907740 0.73 CYP1A2 (0.39) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
Cyclopentane SCHEMBL27697390 0.72 FAAH (0.50) CES1CES2ALDH1A1TP53MEN1
SCHEMBL10141113 0.72 TSHR (0.31) ALDH1A1CYP1A2CYP2C19TDP1
SCHEMBL29242032 0.71 CES1 (0.42) CES1CES2ALDH1A1TP53MEN1
SCHEMBL28471629 0.70 CES1 (0.38) CES1CES2ALDH1A1TP53MEN1
SCHEMBL2478384 0.70 CES2 (0.45) CES1CES2ALDH1A1MEN1KMT2A
SCHEMBL4678177 0.70 MAPT (0.41) ALDH1A1MEN1KMT2AFAAH
SCHEMBL6312935 0.69 GNAI3 (0.50) CES1CES2ALDH1A1MEN1KMT2A
SCHEMBL6264306 0.68 GNAI3 (0.42) CES1CES2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101155803-A Method for obtaining a pharmaceutically active compound (irbesartan) and its synthesis intermediate INKE SA (ES) 2008-04-02 CN disclosed